Phillips-Medisize, a Molex company, will be exhibiting at K39 in hall 8a during COMPAMED 2017. COMPAMED takes place simultaneously with the Medica exhibition on November 13-16 in Düsseldorf. Come visit the booth to see the expanded and integrated Phillips-Medisize and Molex capabilities.
 
Phillips-Medisize, now with the added capabilities of Molex, provides medical OEMs with a one stop location for all its device strategy, design, and development and manufacturing services. Molex is one of the world’s largest interconnect producers, which designs and manufactures electronic, electrical and fiber optic systems and solutions. Molex’s global scale in electronics, and Phillips-Medisize’s device development and manufacturing capabilities are unparalleled.
 
At COMPAMED, come see the end-to-end solutions in, therapeutic combination product drug delivery devices, connected health monitoring equipment solutions, and high-performance diagnostics imaging.
 
Phillips-Medisize is increasingly engaged with future healthcare solutions, in which end-to-end connectivity begins to play an ever-increasing role. Phillips-Medisize’s Chief Technology Officer, Bill Welch, maintains that Connected Health solutions should be developed around therapy specific interfaces that build compelling user experiences.
 
Phillips-Medisize helped develop the first FDA approved, fully connected delivery system approved in the U.S. Similar systems are expected to be released in the next 12-24 months. Welch adds, “We continue to be very focused on partnerships built on innovation, as well as our continuum of contract services for digital interfaces to maximize the patient and caregiver experience. Phillips-Medisize, now a Molex company, has vertically integrated Molex electronics into our existing capabilities. Customer response has already been extremely positive. We will continue to focus on bringing Connected Health solutions to market for our customers, across a broad range of device types and annual volumes with our 360 degree solutions experience.”